MPR

Batoclimab Misses Primary Proptosis Endpoint in Phase 3 TED Trials

Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...
Seeking Alpha

Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful ...
Clinical Trials Arena on MSN

Dizal’s phase III NSCLC trial of Zegfrovy meets primary endpoint

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.
Seeking Alpha

Genentech’s Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...
Nasdaq

Vera Therapeutics Reports Positive Results from ORIGIN Phase 3 Trial of Atacicept for IgA Nephropathy, Meeting Primary Endpoint

Vera Therapeutics, Inc. announced that its ORIGIN Phase 3 trial for atacicept, a treatment for immunoglobulin A nephropathy (IgAN), achieved its primary endpoint by demonstrating a significant ...
Nasdaq

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

TARRYTOWN, N.Y. and PARIS, May 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Phase 3 trial, AERIFY-1, evaluating the investigational use ...
Benzinga.com

Sanofi Asthma Drug Misses Primary Goal, Plans For Pivotal Study

Sanofi SA (NASDAQ:SNY) on Tuesday shared progress from its mid- to late-stage respiratory pipeline. The French drug maker reported preliminary results from the TIDE-Asthma phase 2 study of amlitelimab ...
Morningstar

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy - For the primary ...